Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project.

التفاصيل البيبلوغرافية
العنوان:	Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project.
المؤلفون:	Shiota M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. shiota.masaki.101@m.kyushu-u.ac.jp., Matsubara N; Department Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Kato T; Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan., Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan., Osawa T; Department of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Abe T; Department of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Shinohara N; Department of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Nishimoto K; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan., Yasumizu Y; Department of Urology, Keio University School of Medicine, Tokyo, Japan., Tanaka N; Department of Urology, Keio University School of Medicine, Tokyo, Japan., Oya M; Department of Urology, Keio University School of Medicine, Tokyo, Japan., Fujisawa T; Department Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Horasawa S; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan., Nakamura Y; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Nonomura N; Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.
المصدر:	World journal of urology [World J Urol] 2024 Sep 18; Vol. 42 (1), pp. 526. Date of Electronic Publication: 2024 Sep 18.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Springer International Country of Publication: Germany NLM ID: 8307716 Publication Model: Electronic Cited Medium: Internet ISSN: 1433-8726 (Electronic) Linking ISSN: 07244983 NLM ISO Abbreviation: World J Urol Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: [Berlin ; New York] : Springer International, 1983-
مواضيع طبية MeSH:	Circulating Tumor DNA/genetics , Circulating Tumor DNA/blood , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Prostatic Neoplasms*/blood, Male ; Humans ; Aged ; Middle Aged ; Predictive Value of Tests ; Algorithms ; Bone Neoplasms/secondary ; Bone Neoplasms/genetics ; Bone Neoplasms/blood ; Japan ; Aged, 80 and over ; Genomics
مستخلص:	Background: Undetectable circulating tumor DNA (ctDNA) is an obstacle to performing comprehensive genomic profiling in daily practice to identify genomic alterations. We investigated the associations between clinicopathological factors and undetectable ctDNA using a commercially available comprehensive genomic profiling assay in metastatic prostate cancer. Patients and Methods: Patients treated with systemic treatment for metastatic prostate cancer were included. ctDNA was analyzed by FoundationOne ^® Liquid CDx at enrollment. The associations between clinicopathological characteristics and ctDNA detection were analyzed. Results: The number of bone metastasis was associated with ctDNA detection (odds ratio [95% confidence interval], 13.6 [1.71-108], P = 0.014). An algorithm predicting ctDNA detection using clinicopathological parameters was created. If ≥ 4 bone metastases were observed, ctDNA detection was estimated to be 98.9%. Among the patients with < 4 bone metastases, if two or three features among ISUP grade group 5, PSA level ≥ 10 ng/ml, and castration resistance were present, the ctDNA detection rate was 96.7% while the ctDNA detection rate was 86.3% if no or only one feature was present. Conclusions: An algorithm created in this study is helpful in determining when to undertake comprehensive genomic profiling assay using blood. (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
References:	Mizuno K, Beltran H (2022) Future directions for precision oncology in prostate cancer. Prostate 82:S86–S96. https://doi.org/10.1002/pros.24354. (PMID: 10.1002/pros.24354356571539942493) Jamal-Hanjani M, Wilson GA, Horswell S, Mitter R, Sakarya O, Constantin T, Salari R, Kirkizlar E, Sigurjonsson S, Pelham R, Kareht S, Zimmermann B, Swanton C (2016) Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol 27:862–867. https://doi.org/10.1093/annonc/mdw037. (PMID: 10.1093/annonc/mdw03726823523) Reichert ZR, Morgan TM, Li G, Castellanos E, Snow T, Dall’Olio FG, Madison RW, Fine AD, Oxnard GR, Graf RP, Stover DG (2023) Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol 34:111–120. https://doi.org/10.1016/j.annonc.2022.09.163. (PMID: 10.1016/j.annonc.2022.09.16336208697) Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C, Du P, Jia S, Yadav S, Horvath LG, Mahon KL, Kwan EM, Fettke H, Yu J, Azad AA (2020) Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMedicine 54:102728. https://doi.org/10.1016/j.ebiom.2020.102728. (PMID: 10.1016/j.ebiom.2020.102728322682767186589) Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN (2018) Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov 8:444–457. https://doi.org/10.1158/2159-8290.CD-17-0937. (PMID: 10.1158/2159-8290.CD-17-093729367197) Choudhury AD, Werner L, Francini E, Wei XX, Ha G, Freeman SS, Rhoades J, Reed SC, Gydush G, Rotem D, Lo C, Taplin ME, Harshman LC, Zhang Z, O’Connor EP, Stover DG, Parsons HA, Getz G, Meyerson M, Love JC, Hahn WC, Adalsteinsson VA (2018) Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3:e122109. https://doi.org/10.1172/jci.insight.122109. (PMID: 10.1172/jci.insight.122109303857336238737) Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC (2019) Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. Prostate 79:701–708. https://doi.org/10.1002/pros.23778. (PMID: 10.1002/pros.23778308653116589085) Antonarakis ES, Tierno M, Fisher V, Tukachinsky H, Alexander S, Hamdani O, Hiemenz MC, Huang RSP, Oxnard GR, Graf RP (2022) Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer. Prostate 82:867–875. https://doi.org/10.1002/pros.24331. (PMID: 10.1002/pros.24331352867289314037) Bando H, Nakamura Y, Taniguchi H, Shiozawa M, Yasui H, Esaki T, Kagawa Y, Denda T, Satoh T, Yamazaki K, Sunakawa Y, Kato T, Goto M, Yuki S, Nishina T, Oki E, Shinozaki E, Matsuhashi N, Takahashi N, Tsuji A, Ohtsubo K, Wakabayashi M, Ikeno T, Hata M, Odegaard JI, Yoshino T (2022) Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer. JCO Precis Oncol 6:e2100535. https://doi.org/10.1200/PO.21.00535. (PMID: 10.1200/PO.21.0053535544728) Mishima S, Nakamura Y, Tukachinsky H, Taniguchi H, Kadowaki S, Kato K, Oki E, Satoh T, Aoki D, Yamazaki K, Esaki T, Ueno M, Nishina T, Sunakawa Y, Denda T, Bando H, Kuramoto N, Horasawa S, Abutani H, Lee JK, Yoshino T (2023) Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN. J Liquid Biop 1:100003. https://doi.org/10.1016/j.jlb.2023.100003. (PMID: 10.1016/j.jlb.2023.100003) Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, Yoshino T, Nonomura N (2024) Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project. BJC Rep 2:28. https://doi.org/10.1038/s44276-024-00049-7. (PMID: 10.1038/s44276-024-00049-7) Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026. (PMID: 10.1016/j.ejca.2008.10.02619097774) Tsechelidis I, Vrachimis A (2022) PSMA PET in imaging prostate cancer. Front Oncol 12:831429. https://doi.org/10.3389/fonc.2022.831429. (PMID: 10.3389/fonc.2022.831429351552628832487)
فهرسة مساهمة:	Keywords: Circulating tumor DNA; Detection; Metastatic prostate cancer
المشرفين على المادة:	0 (Circulating Tumor DNA)
تواريخ الأحداث:	Date Created: 20240918 Date Completed: 20240918 Latest Revision: 20240918
رمز التحديث:	20240918
DOI:	10.1007/s00345-024-05240-6
PMID:	39292288
قاعدة البيانات:	MEDLINE

Find this article in full text from Springer Verlag.

Full Text Finder

الوصف
تدمد:	1433-8726
DOI:	10.1007/s00345-024-05240-6